SCHEMBL1937822

SCHEMBL1937822

CC1(OC(=O)N2CCC(COc3c(F)cc(-c4ccc(S(C)(=O)=O)cc4)cc3F)CC2)CC1

nearest known ligand 0.48

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 19/20 0.48
SLC6A9 P48067 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12375468 0.88 GPR119 (0.48) GPR119CYP2C9CYP2C19
SCHEMBL1938312 0.87 GPR119 (0.61) GPR119
SCHEMBL1937388 0.85 SLC6A9 (0.46) GPR119SLC6A9
SCHEMBL903900 0.83 GPR119 (0.39) GPR119CYP2C9CYP2C19
SCHEMBL1937856 0.82 GPR119 (0.53) GPR119CYP2C9CYP2C19
SCHEMBL903897 0.82 GPR119 (0.40) GPR119
SCHEMBL1104001 0.81 GPR119 (0.48) GPR119CYP2C9CYP2C19
SCHEMBL1935580 0.80 GPR119 (0.42) GPR119
SCHEMBL1937392 0.80 GPR119 (0.43) GPR119
SCHEMBL1092380 0.80 GPR119 (0.43) GPR119CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2331503-B1 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2013-08-21 EP claimed
US-8334288-B2 4-phenoxymethylpiperidines as modulators of GPR119 activity IRM LLC (BM) 2012-12-18 US claimed
JP-2011527701-A 2011-11-04 JP claimed
US-20110190298-A1 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2011-08-04 US claimed
EP-2331503-A1 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2011-06-15 EP claimed
WO-2010006191-A1 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2010-01-14 WO claimed
US-20160051688-A1 GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING G PROTEIN-COUPLED RECEPTOR ACTIVITY UNIV INDIANA RES & TECH CORP (US) 2016-02-25 US disclosed
US-9145451-B2 Glucagon superfamily peptides exhbiting G protein coupled receptor activity INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2015-09-29 US disclosed
EP-2331503-B1 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2013-08-21 EP disclosed
EP-2331503-B1 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2013-08-21 EP disclosed
US-20130116172-A1 GLUCAGON SUPERFAMILY PEPTIDES EXHBITING G PROTEIN COUPLED RECEPTOR ACTIVITY MARCADIA BIOTECH, INC. (US) 2013-05-09 US disclosed
EP-2568993-A1 GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING G PROTEIN-COUPLED RECEPTOR ACTIVITY Indiana University Research and Technology Corporation (US) 2013-03-20 EP disclosed
US-8334288-B2 4-phenoxymethylpiperidines as modulators of GPR119 activity IRM LLC (BM) 2012-12-18 US disclosed
WO-2011143208-A1 GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING G PROTEIN-COUPLED RECEPTOR ACTIVITY INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2011-11-17 WO disclosed
US-20110190298-A1 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2011-08-04 US disclosed
US-20110190298-A1 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2011-08-04 US disclosed
US-20110190298-A1 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2011-08-04 US disclosed
EP-2331503-A1 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2011-06-15 EP disclosed
WO-2010006191-A1 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2010-01-14 WO disclosed
WO-2010006191-A1 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2010-01-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116172-A1 GLUCAGON SUPERFAMILY PEPTIDES EXHBITING G PROTEIN COUPLED RECEPTOR ACTIVITY GCGR, GLP1R, GIPR GPR119 4/4885SLC6A9 1914/4885CYP2C9 3640/4885
US-20160051688-A1 GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING G PROTEIN-COUPLED RECEPTOR ACTIVITY GCGR, GLP1R, GIPR GPR119 4/4885SLC6A9 2015/4885CYP2C9 3748/4885
US-20110190298-A1 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY GPR119, GPR4, GPR180 GPR119 1/4885SLC6A9 1995/4885CYP2C9 1724/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.